Method of using SAHA and Erlotinib for treating cancer
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
1 . A method of treating cancer in a subject in need thereof comprising administering to the subject a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), represented by the structure:
or a pharmaceutically acceptable salt or hydrate thereof, and a tyrosine kinase inhibitor, Erlotinib, represented by the structure:
or a pharmaceutically acceptable salt or hydrate thereof, wherein the histone deacetylase inhibitor and the tyrosine kinase inhibitor are administered in amounts effective for treating the cancer.
2 . The method of claim 1 , wherein the histone deacetylase inhibitor and the tyrosine kinase inhibitor are administered concurrently.
3 . The method of claim 1 , wherein the histone deacetylase inhibitor is administered prior to administering the tyrosine kinase inhibitor.
4 . The method of claim 1 , wherein the histone deacetylase inhibitor is administered after administering the tyrosine kinase inhibitor.
5 . The method of claim 1 , wherein the histone deacetylase inhibitor and the tyrosine kinase inhibitor are administered orally.
6 . The method of any one of claims 1 - 5 , wherein suberoylanilide hydroxamic acid (SAHA) and Erlotinib are administered.
7 . The method of any one of claims 1 - 6 , wherein the cancer is non-small cell lung cancer.
8 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at a dose of 300 mg, wherein the administration is continuous.
9 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at a dose of 200 mg for at least one period of 3 out of 7 days.
10 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at a dose of 300 mg for at least one period of 3 out of 7 days.
11 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at a dose of 400 mg for at least one period of 3 out of 7 days.
12 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at a dose of 500 mg for at least one period of 3 out of 7 days.
13 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered twice daily at 200 mg per dose for at least one period of 3 out of 7 days.
14 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered twice daily at 300 mg per dose for at least one period of 3 out of 7 days.
15 . The method of any one of claims 9 - 14 , wherein the histone deacetylase inhibitor is administered for at least one period of 3 out of 7 days for two weeks, followed by a two-week rest period.
16 . The method of any one of claims 9 - 14 , wherein the histone deacetylase inhibitor is administered for at least one period of 3 out of 7 days for three weeks, followed by a one-week rest period.
17 . The method of any one of claims 9 - 14 , wherein the histone deacetylase inhibitor is administered for at least one period of 3 out of 7 days for one week, followed by a one-week rest period.
18 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered twice daily at 300 mg per dose for at least one period of 7 out of 14 days.
19 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered once daily at 300 mg per dose for at least one period of 14 out of 28 days.
20 . The method of any one of claims 1 - 19 , wherein the tyrosine kinase inhibitor is administered once daily at a dose of 50 mg, wherein the administration is continuous.
21 . The method of any one of claims 1 - 19 , wherein the tyrosine kinase inhibitor is administered once daily at a dose of 100 mg, wherein the administration is continuous.
22 . The method of any one of claims 1 - 19 , wherein the tyrosine kinase inhibitor is administered once daily at a dose of 150 mg, wherein the administration is continuous.
23 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered at a total daily dose of up to 400 mg and the tyrosine kinase inhibitor is administered at a total daily dose of up to 150 mg.
24 . The method of any one of claims 1 - 7 , wherein the histone deacetylase inhibitor is administered at a total daily dose of up to 600 mg and the tyrosine kinase inhibitor is administered at a total daily dose of up to 150 mg.
25 . An oral pharmaceutical composition comprising a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), represented by the structure:
or a pharmaceutically acceptable salt or hydrate thereof, and a tyrosine kinase inhibitor, Erlotinib, represented by the structure:
or a pharmaceutically acceptable salt or hydrate thereof, and optionally one or more pharmaceutically acceptable excipients.
26 . The pharmaceutical composition of claim 25 that comprises about 100 mg of SAHA and about 50 mg of Erlotinib.
27 . The pharmaceutical composition of claim 25 , which comprises suberoylanilide hydroxamic acid (SAHA) and Erlotinib.